Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for curing corneal and conjunctival disease

A therapeutic agent, corneal technology, applied in sensory diseases, organic active ingredients, medical preparations containing active ingredients, etc., can solve problems such as no hint of biphenylmethyl derivatives

Inactive Publication Date: 2008-04-16
SANTEN PHARMA CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there is no report on the study of the pharmacological effects of the above-mentioned biphenylmethyl derivatives on eye diseases, especially on keratoconjunctival lesions, and there is no suggestion at all that the biphenylmethyl derivatives with what basic chemical structure have effects on keratoconjunctival lesions. it works

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for curing corneal and conjunctival disease
  • Drug for curing corneal and conjunctival disease
  • Drug for curing corneal and conjunctival disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0083] The results of pharmacological tests and preparation examples are given below. The above examples are used to better understand the present invention, and do not limit the scope of the present invention.

[0084] [pharmacological test]

[0085] Curative Effect Trial of Corneal Lesions

[0086] Using male SD rats, a corneal lesion model was produced based on the method of Fujihara et al. (Invest. Ophthalmol. Vis. Sci 42(1): 96-100 (2001)). After the corneal lesion model was prepared, the corneal lesion was scored and judged based on the method of Murakami et al. (Shin Ophthalmology 21(1):87-90 (2004)), and the improvement rate of the corneal lesion after instillation was calculated.

[0087] (experimental method)

[0088] Male SD rats were given general anesthesia with pentobarbital sodium, and then the extraorbital lacrimal glands were removed to induce corneal lesions for 2 months.

[0089] Then, 4'-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-n-propylbenzimidazol-1-y...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

The purpose is to provide a therapeutic agent for a corneal / conjunctival disorder. A compound represented by the general formula (1) or a salt thereof shows an excellent ameliorating effect in a corneal disorder model, and therefore is useful as a therapeutic agent for a corneal / conjunctival disorder such as dry eye, corneal ulcer, keratitis and conjunctivitis. In the general formula, the ring Y represents a substituted or unsubstituted nitrogenated heterocyclic ring; R1 represents a carboxyl group or a substituted or unsubstituted nitrogenated 5-membered heterocyclic ring; and R2 and R3 independently represent a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkylcarbonyl group.

Description

technical field [0001] The present invention relates to dry eye, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defect, conjunctival epithelial defect, keratoconjunctivitis sicca, superior keratoconjunctivitis limbickeratoconjunctivitis), filamentary keratitis (Filamentary Keratitis) and other keratoconjunctival diseases, the therapeutic agent contains a biphenylmethyl derivative or a salt thereof as an active ingredient. Background technique [0002] The cornea is a transparent, avascular tissue with a diameter of about 1 cm and a thickness of about 1 mm. In addition, the conjunctiva is the mucous membrane that covers the surface of the eyeball behind the limbus and the back of the eyelid. Significant impact on visual function when known corneal or conjunctival lesions. Keratoconjunctival disease caused by various diseases such as corneal ulcer, keratitis, conjunctivitis, dry eye, etc., adversely affects the normal remodeling...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/41A61P27/02
CPCA61K31/41A61P27/02A61K31/4152
Inventor 柴垣圭一平井慎一郎中村雅胤
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com